Objective of the trial is to assess dose-dependency, efficacy and safety and to estimate
optimum dosage for confirmatory study of CWP-0403 50mg, 100mg given twice daily for 12 weeks
to type 2 diabetes patients who are insufficiently controlled by diet and exercise in
comparison to placebo.